Literature DB >> 34081207

Quality of Diabetes Care in the USA.

Ben Alencherry1, Dennis Bruemmer2,3.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the current quality of diabetes care in the USA, discuss barriers to guideline-recommended treatment adherence, and outline strategies for the improvement in care. RECENT
FINDINGS: Current treatment guidelines highlight the importance of glycemic control, use of novel medications with proven cardiovascular efficacy, and multifactorial cardiovascular risk factor intervention for the treatment of diabetes and associated complications. Albeit proven evidence for these guidelines, the vast majority of patients with diabetes remain insufficiently treated. Interventions to improve outcomes require focus on care delivery systems, physician behavior, and patient-centered approaches. De-fragmenting care systems to form collaborative, multi-specialty teams, use of standardized and comprehensive treatment algorithms, development of quality assessment tools, avoiding physician therapeutic inertia, and addressing patient barriers, including lack of perceived benefit, insufficient diabetes education and access to care, and medication costs, represent key objectives to improve diabetes care and outcomes. Clinical research in standardized trials has proven the feasibility to reduce morbidity and mortality associated with diabetes. Implementing models of care to disseminate these encouraging research findings to the wider population and to overcome barriers to achieving guideline-recommended treatment goals should be the objective to improve our current quality of diabetes care in the USA.

Entities:  

Keywords:  Cardiovascular; Diabetes; Quality of care

Mesh:

Year:  2021        PMID: 34081207     DOI: 10.1007/s11886-021-01503-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  59 in total

1.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2017-04-13       Impact factor: 91.245

2.  Resurgence in Diabetes-Related Complications.

Authors:  Edward W Gregg; Israel Hora; Stephen R Benoit
Journal:  JAMA       Date:  2019-05-21       Impact factor: 56.272

3.  Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis.

Authors:  Jose Miguel Baena-Díez; Judit Peñafiel; Isaac Subirana; Rafel Ramos; Roberto Elosua; Alejandro Marín-Ibañez; María Jesús Guembe; Fernando Rigo; María José Tormo-Díaz; Conchi Moreno-Iribas; Joan Josep Cabré; Antonio Segura; Manel García-Lareo; Agustín Gómez de la Cámara; José Lapetra; Miquel Quesada; Jaume Marrugat; Maria José Medrano; Jesús Berjón; Guiem Frontera; Diana Gavrila; Aurelio Barricarte; Josep Basora; Jose María García; Natalia C Pavone; David Lora-Pablos; Eduardo Mayoral; Josep Franch; Manel Mata; Conxa Castell; Albert Frances; María Grau
Journal:  Diabetes Care       Date:  2016-08-04       Impact factor: 19.112

4.  Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus.

Authors:  Joshua M Stolker; Dazhong Sun; Darcy G Conaway; Philip G Jones; Frederick A Masoudi; Pamela N Peterson; Harlan M Krumholz; Mikhail Kosiborod; John A Spertus
Journal:  Am J Cardiol       Date:  2010-02-20       Impact factor: 2.778

5.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2017-01-17       Impact factor: 3.443

Review 6.  Intensive glycemic control and cardiovascular disease: an update.

Authors:  Aparna Brown; L Raymond Reynolds; Dennis Bruemmer
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

7.  Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

Review 8.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

9.  Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.

Authors:  Andy Menke; Sarah Casagrande; Linda Geiss; Catherine C Cowie
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

10.  Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction.

Authors:  Joshua M Stolker; John A Spertus; Darren K McGuire; Marcus Lind; Fengming Tang; Philip G Jones; Silvio E Inzucchi; Saif S Rathore; Thomas M Maddox; Frederick A Masoudi; Mikhail Kosiborod
Journal:  Diabetes Care       Date:  2012-03-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.